It has been a great privilege to be Vice-Provost (Enterprise) at UCL and inevitably as I pack my bags to make the long trip from Gordon Street to the Wellcome Trust on Euston Road, I have been reflecting on the last five years. So much has changed and so much has been achieved by UCL.
Novozymes Biopharma to offer drug-albumin conjugation platform in collaboration with UCLB spinout ThioLogics
14 May 2014
ThioLogics, a UCL Business company, spun-out of the UCL Department of Chemistry has entered into a new collaboration with Novozymes Biopharma.
The collaboration brings together Novozymes’ modified recombinant human albumin (rAlbumin) Veltis technology with ThioLogics’ site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
As part of the partnership, Novozymes’ customers will be given valuable access to conjugation specialists, providing assurance that they will receive the highest level of support to design stable and efficacious drug candidates.
“Combining the benefits of Novozymes’ and ThioLogics’ technology platforms means that we can now work with more customers across a wider range of drug candidates,” says Dermot Pearson, Marketing Director at Novozymes Biopharma. He continues, “Together we are creating new opportunities for customers by providing them with a single access point to link Novozymes’ Veltis albumins and ThioLogics’ conjugation platform, to improve their products.
Exclusively marketed through Novozymes Biopharma, the collaboration will allow Novozymes to apply its technology to molecules that are not amenable to a genetic fusion approach, such as synthesized peptides and small molecules in oncology and rheumatoid arthritis. Combining the advantages of the two technologies will enable the versatile modification of these therapeutic molecules to yield well-defined, stable and consistent conjugates.
“We are delighted to announce ThioLogics’ unique collaboration with Novozymes, which will expand the capabilities of our technology platform beyond antibody-drug conjugates,” comments Dr Chris Williams, Business Development Manager at ThioLogics.
Professor Stephen Caddick, one of the Founders of ThioLogics and Vice-Provost (Enterprise) at UCL said, “For the first time, the linking of our two platforms will make well-defined and stable albumin conjugation a reality, providing manufacturers with serum stable drug conjugates with tailored pharmacokinetics to maximize the therapeutic potential of their products.
Combining the Veltis platform with ThioLogics’ next generation maleimide technology, in addition to Novozymes recently announced partnership with Almac, provides Veltis with a strong position in the field of drug conjugation and supports the use of the technology in peptide and protein fusion.